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The aim of the current study was to investigate the effect of 14-membered ring macrolide clar-
ithromycin (CAM) on migration induced by human plasma fibronectin (HFn) or on contraction of
human fetal lung fibroblasts (HFL-1).
Methods and results: Using the blindwell chamber technique, CAM (105 M) inhibited the
migration of HFL-1 60.2 4.0% (p< 0.05). Other antibiotics, such as ampicillin, minocycline
or azithromycin had no effects on HFL-1 migration. The effect of CAM was concentration
dependent. HFL-1 migration, stimulated by TXA2 analog was also inhibited by CAM. Clarithro-
mycin had no effect on HFL-1 mediated gel contraction that was another function of fibroblast
at the wound area.
Conclusions: Clarithromycin may contribute to the regulation of the wound healing response
following injury by inhibiting fibroblast migration. These results could represent the thera-
peutic benefits of CAM.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
After tissue injury, fibroblast migration from surrounding
peri-wound connective tissue into the site of wound area
and fibroblast contraction at wound area plays an impor-
tant role in repairing process. Under normal circumstances,
fibroblasts are quiescent mesenchymal cells. However, in
some inflammatory processes, fibroblasts become activated3815 5411; fax: þ81 03 3815
.ac.jp (T. Kohyama).
8 Elsevier Ltd. All rights reservedand excess number of their migration would cause replace-
ment of normal parenchymal elements of tissue to fibrosis.1
These changes can distort normal tissue architectural rela-
tionship, can compromise organ function and can cause
fibrosis. One of the therapeutic objectives in fibrotic
disease is to reduce the local inflammatory response
through the reduction of excess migration and contraction
of fibroblast.
The macrolide is a group of antibiotics which have unique
large macrocyclic lactone ring. Macrolide inhibits bacterial
protein biosynthesis by binding to the subunit 50S of the
bacterial ribosome. Macrolide is effective against Gram-
positive cocci, mycoplasma, mycobacteria, and chlamydia..
1770 T. Kohyama et al.Among them, 14-membered ring macrolides, however,
have curious effects on inflammatory processes. Low dose
erythromycin therapy improves the survival or lung function
of patient with intractable diseases, such as diffuse
panbronchiolitis (DPB) which is mostly recognized in Asian
and cystic fibrosis which is most common inherited disease
in Caucasian.2,3 According to the data of inhibition of
inflammatory cytokine productions,4e6 changing the Th1/
Th2 cytokine ratio3 and effectiveness in cancer studies,7e9
macrolide effects might be immunomodulatory activities.
In vivo study also shows that macrolide might prevent the
lung injury and fibrosis in bleomycin-challenged mouse.10
However, the precise mechanism of 14-membered ring
macrolide has not been elucidated clearly yet. The current
study evaluated the potential effects of CAM on fibroblast-
mediated repair responses by using in vitro models of tissue
remodeling. Our findings, therefore, support the notion
that CAM may play a role in the remedy of remodeling of
the lung.
Materials and methods
Materials
Clarithromycin was generously provided by Taisho Pharma-
ceutical Co. (Tokyo, Japan). Ampicillin (ABPC), minocycline
(MINO) and azithromycin (AZM) were purchased from SIGMA
(St. Louis, MO). KT5720 was purchased from Calbiochem
(San Diego, CA). Ampicillin (102 M), MINO (2 102 M) was
dissolved into dH2O, CAM (5 103 M) and AZM(103 M)
were dissolved into 100% ethanol and KT5720 was dissolved
into dimethylsulfoxide (DMSO) at 102 M for stock reagents.
According to the reports of previous experiments,11,5,4,12
we chose the concentration of each drugs as follows: MINO
(106 M); ABPC (105 M); CAM (105 M); AZM (105 M). Those
concentrations were around the clinical plasma levels
achieved pharmacologically after using standard dosage.
Tissue culture supplements and media were purchased
from GIBCO (Life Technologies, Grand Island, NY). Fetal
calf serum (FCS) was purchased from Biofluid (Rockville,
MD). Human fetal lung fibroblasts (HFL-1) were obtained0
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Figure 1 MTT assay. Vertical axis, expressed as percentage of c
shown are meansþ SEM for three separate experiments. Each confrom the American Type Culture Collection (Rockville, MD).
A second strain of human fetal lung fibroblasts (WI-38) was
purchased from Health Science Research Resources Bank
(Osaka, Japan). The cells were cultured in 100 mm tissue
culture dishes (FALCON; BectoneDickinson Labware,
Lincoln Park, NJ) in Dulbecco’s modified Eagle medium
(DMEM, Gibco, Grand Island, NY), supplemented with 10%
FCS, 50 U/ml penicillin G sodium and 50 mg/ml strepto-
mycin sulfate (penicillinestreptomycin, GIBCO) in a humid-
ified atmosphere at 37 C and 5% CO2. The fibroblasts were
routinely passaged every 4 or 5 days and cells were used
between passage 13 and 21 in all experiments. Sub-
confluent fibroblasts were removed from the dishes by
treatment with 0.05% trypsin in 0.53 mM ethylenediamine-
tetraacetic acid and stop the reaction by soybean trypsin
inhibitor (GIBCO). After centrifuging to remove the trypsin
inhibitor, cells were re-suspended in DMEM without serum.
Cell toxicity examination
Preliminary, MTT assay was performed to test the toxicity
of reagents and diluents. Briefly, after being cultured for
6 h with each reagent in 96 well culture plate, the medium
were discarded and 100 ml MTT solution (200 mg/ml in
DMEM) per well was added. After another 4 h incubation,
MTT solution were discarded and 100 ml of DMEM per well
was added to melt formazan crystal. The OD values were
read at 630 nm wavelength.
Fibroblast migration
HFL-1 and WI-38 migrations were assessed by the Boyden
blindwell chamber system13 using 48-well chambers (Nucle-
opore, Cabin John, MD). The chemoattractant fibronectin
was placed in the bottom chamber. The upper and lower
portions of the chamber were separated by the 8 mm pore
filter (Nucleopore, Pleasanton, CA) coated with 0.1%
gelatin (Bio Rad, Hercules, CA). The top manifold was
placed and human fetal lung fibroblasts (1.0 106 ml in
DMEM without serum) were loaded into the upper wells of
the chamber with the desired concentration of CAM or0
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Figure 2 Inhibition of fibroblast migration by CAM. Migration
of HFL-1 fibroblasts was measured with blindwell assay system
using human fibronectin with or without the CAM (105 M).
Vertical axis, fibroblast migration expressed as number of cells
migrated per 5 high-power fields; horizontal axis: concentra-
tion of fibronectin. Data shown are means SEM for represen-
tative data from three separate experiments. Each
experiments for migration in triplicate. (*p< 0.05).
Clarithromycin inhibits fibroblast migration 1771other additives. The chamber was then incubated at 37 C
in a moist, 5% CO2 atmosphere. Except the time course
experiment chambers were incubated for 6 h, after which
the cells on the top of the filter were removed by scraping.
The filter was then fixed, stained with Diff Quik stain (Inter-
national reagents CORP, Kobe, Japan), and mounted on
a glass microscope slide. Migration was assessed by count-
ing the number of cells in 5 high-power fields using a light
microscope. Triplicate wells were prepared in each experi-
ment for every condition. Replica experiments were
performed with separate cultures of cells on separate
occasions.0
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Figure 3 Inhibition of fibroblast migration by CAM: concentratio
attractant. Clarithromycin was added to the fibroblasts at various c
top wells of the chemotaxis chamber. (A) HFL-1, (B) WI-38. Vertica
control. Horizontal axis: CAM concentration. Data shown are mean
chemotactic activity in triplicate. (*p< 0.05).Collagen gel contraction assay
To test the CAM effect on contractility of fibroblast,
another function of fibroblast, fibroblast-mediated gel
contraction was measured according to a method devel-
oped by Bell and coworkers.14 Collagen gels were prepared
as described previously.15 Briefly, Type I collagen that was
extracted from rat tail,16 distilled water, 4 DMEM and
fibroblast suspensions were mixed by pipetting so that the
final mixture resulted in 0.75 mg/ml of collagen,
3 105 fibroblasts/ml gel and a physiologic ionic strength
of 1 DMEM. A 500 ml portion of the gel solution was then
cast into each well of a 24-well tissue culture plate
(FALCON). After gelation, the gels were released into
60 mm tissue culture dishes (FALCON) containing 5 ml of
DMEM with designed concentration of CAM. The floating
gels were cultured for up to 5 days, and the ability of the
fibroblasts to contract the gels was determined by quanti-
fying the area of the gels daily using an image analyzer
(ATTO, Tokyo, Japan).
Statistical analysis
Samples with multiple comparisons were analyzed for
significance using analysis of variance (ANOVA). Pair-wise
comparisons were analyzed by independent two sample t-
test where the critical value is adjusted for multiple
comparisons by the Tukey test. (p< 0.05) Summary data
are expressed as mean SEM.
Results
MTT assay showed that each concentration of the reagents
and diluents using these experiments were not toxic for the
fibroblasts (Fig. 1).
The migration was measured by using the blindwell assay
system. Fibronectin put in the lower wells directed the0
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Figure 4 Clarithromycin effect on the chemokinesis of HFL-1.
Same concentrations of human fibronectin were placed both
above and below the filter. There is no chemoattractant
gradient. Vertical axes: fibroblast migration expressed as
number of cells migrated per 5 high-power fields; Horizontal
axis: fibronectin concentration of both sides. Data shown are
means SEM for representative data from three separate
experiments. Each experiments for migration in triplicate.
(*p< 0.05).
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1772 T. Kohyama et al.HFL-1 migration in concentration dependent fashion. Clar-
ithromycin (105 M) added in the top wells inhibited the
HFL-1 migration at 10 and 20 mg/ml of fibronectin (Fig. 2).
Clarithromycin inhibited the fibronectin (20 mg/ml)
directed migration in concentration dependent manner.
The inhibitory effect reached significant by 106 M of CAM0
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Figure 5 Inhibition of fibroblast migration by CAM: time
course. Fibronectin (20 mg/ml) was used as the chemoattrac-
tant. Clarithromycin was added to the fibroblasts in the top
wells at various concentrations. The chambers were incubated
and after varying times, removed for staining and counting.
Vertical axis: fibroblast migration expressed as number of cells
migrated per 5 high-power fields; horizontal axis: time in
hours. Data shown are means SEM for representative data
from three separate experiments. Each experiment for migra-
tion in triplicate (*p< 0.05).on HFL-1 (control, 100%; CAM 106 M, 73.7 7.3%,
p< 0.05) and by 105 M of CAM on WI-38 (control, 100%;
CAM 105 M, 46.2 15.5%, p< 0.05) (Fig. 3).
To determine if CAM inhibit chemokinesis, same concen-
trations of human fibronectin were placed both above and
below the filter. The meaning of this experiment shows
there is no chemoattractant gradient (chemokinesis) even
in the presence of increasing concentrations of fibronectin
above and below the filter. Clarithromycin also inhibited
chemokinesis (at fibronectin 10 mg/ml; control, 59.3 2.9;
CAM 105 M, 40.3 0.9%, p< 0.05) (Fig. 4).
In the time course assay, the accumulation of the HFL-1
continued to increase even at the end point we tested
(12 h). Clarithromycin (105 M) inhibited the HFL-1 migra-
tion at 6 h (control, 76.0 5.6; CAM, 105 M 48.0 7.1%,
p< 0.05) (Fig. 5).
To elucidate the inhibitory effects of CAM on the
activated fibroblast as in the inflammatory area, we tested
the CAM effect on the fibroblast activated by TXA2 analog
U46619. Clarithromycin (105 M) significantly inhibited the
U46619 (2 107 nM) activated fibroblasts migration (con-
trolZ 100%; U46619, 130.3 8.2; U46619 plus CAM
105 M, 53.1 2.5%, p< 0.05) (Fig. 6).0
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Figure 6 Effect of CAM on stimulatory cells by TXA2 analog
U46619. HFL-1 were pre-incubated with U46619 (2 107 M)
in monolayer culture for 1 h and then harvested for migration.
Fibronectin (20 g/ml) was used as chemoattractant. Clarithro-
mycin (105 M) was added to the fibroblasts in the top wells
with 2 107 M of U46619. Vertical axis, fibroblast migration
expressed as percentage of control. Data are meansþ SEM
for triplicate cultures each assayed for migration in triplicate.
(*p< 0.05).
Clarithromycin inhibits fibroblast migration 1773We have tried to check another antibiotics Ampicillin
(ABPC) (105 M), minocycline (MINO) (106 M) and azithro-
mycin (AZM) (105 M) effects on human lung fibroblast
migration. Among them CAM but other antibiotics inhibited
the migration of HFL-1. (controlZ 100%; ABPC 90.7 5.1%;
MINO, 105.6 9.7%; CAM 45.8 4.6% p< 0.05; AZM
99.5 15.3%) (Fig. 7A). As azithromycin is one of the mac-
rolides, we confirmed its effect with several concentra-
tions. Azithromycin had no effect on HFL-1 migration
(Fig. 7B).
Among the fibroblast functions in the wound area,
contractility is also important for repair and remodeling
process. To elucidate the CAM effect on it, we have used
gel contraction assay system. Clarithromycin had no effect
on fibroblast contraction in the gel (Fig. 8).
There is no clear mechanism report of CAM effect on
fibroblast migrations. Most of the reagents which inhibit the
fibroblast migrations are related to the activation of
protein kinase A.17,18 To determine if the inhibition of
migration toward fibronectin by CAM is by way of PKA
pathway, we assessed the PKA inhibitor KT5720 with CAM.
As there is the report which showed that KT5720 block
the inhibitory effect of PGD2 on fibroblast migration,
18 we
put the PGD2 examination as control. KT5720 did not block
the inhibitory effect of CAM on HFL-1 migration (Fig. 9).
Discussion
The current study demonstrates that CAM was capable of
inhibiting fibroblast migration to human fibronectin. The
effects by CAM were concentration dependent. Clarithro-
mycin also inhibited the TXA2 analog U46619 stimulated
migration of HFL-1. Moreover, CAM inhibited both human
lung fibroblast chemotaxis and chemokinesis. Clarithromy-
cin had no effect on contractility of fibroblast that is impor-
tant function for end stage of wound healing.
The accumulation of fibroblasts to the wound site is
often a key event in both normal repair and in the
development of fibrosis.0
50
100
150
%
C
o
n
t
r
o
l
*
AB
PC
 1
0-
5 
M
M
IN
O
 1
0-
6 
M
CA
M
 1
0-
5 
M
AZ
M
 1
0-
5 
M
co
n
tro
l
A
Figure 7 Effects of other antibiotics on fibroblast chemotaxis. HF
assay system. (A) Ampicillin (ABPC) (105 M), minocycline (MINO)
added to the top of each well. (B) Several concentration of AZM
percentage of control. Horizontal axis: each condition. Data are m
in triplicate. (*p< 0.05).In the process of it, fibroblast migration, proliferation
and contraction are essential events. Under normal repair
process, adequate numbers of fibroblasts migrate to the
wound area.
However, an excess accumulation of fibroblasts and
excess deposition of extracellular matrix produced by
fibroblast results in replacement of the normal tissue
parenchyma with fibrotic scar, which results in irreversible
distortion of the lung’s architecture and compromising
organ function.19,1
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive and fetal lung disorder. The mean prognosis after
diagnosis is ranging from 3 to 5 years.20 The treatments
employed currently are steroids and cytotoxic agents,
however, both of them have not been proven to prolong
survival or improve pulmonary function among patients
with IPF. The critical phenomenon which related prognosis
is ongoing epithelial damage and persistent fibroblastic
proliferation.21
In this context, the reagent which controls the fibroblast
function might be a good medicine.
Clarithromycin, a 14-membered ring macrolide, is known
as an antibiotic. Recently we have used this medicine as
immunomodulatory drug. This opinion is supported by in
vitro and in vivo data. Clarithromycin decreases the
production of cytokines,4e6 changes the Th1/Th2 cytokine
ratio3 and prevents the lung injury and fibrosis in bleomy-
cin-challenged mouse.10
These reports will give us hints to explore that clari-
thromycin might make biological actions on the cells which
are important for wound healing or remodeling in the
inflammatory milieu.
Our data showed that CAM inhibited fibroblast migration.
This is important effect for inhibiting the remodeling.
Fibronectin of plasma is chemotactic for HFL-1 andWI-38.
For the reason mentioned below, we used the fibro-
nectin for chemoattractant of fibroblasts. Fibronectin, one
of the extracellular matrixes, is mainly produced by
fibroblasts22 and soluble in plasma and tissues. Fibronectin0
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Figure 8 Effect of CAM on collagen gel contraction. HFL-1
was cast into gel and floated on the conditioned media. The
size of gel area was measured every day. Vertical axis: gel
size as percentage of initial area; horizontal axis, time after
release (day). Data shown are means SEM for representative
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1774 T. Kohyama et al.content of the wound matrix is much higher than that of the
adjacent tissue.23 It is reasonable for fibroblast and inflam-
matory cells, such as neutrophil and monocyte, to migrate
into the wound area.24e28 Recruiting the inflammatory cells
is important for management of infection and removal of0
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Figure 9 Effect of protein kinase A inhibitor on CAM reducing
HFL-1 migration. HFL-1 migration was performed in the Boyden
blind well chamber assay system. Protein kinase A inhibitor
KT5720 was added to the upper wells with or without CAM.
KT5720 effect on PGD2 was the positive control of this assay.
(*p< 0.05).tissue debris in the wound area. Fibronectin helps platelet
to attach to collagen29 and enmeshed in blood clots28 at the
defect of tissue. Moreover fibronectin mediate fibroblasts
attachment to collagen.30 Taken together, these findings
suggest that fibronectin is very important for wound
healing.
Our data clearly showed that CAM inhibited the migra-
tion of even the stimulated fibroblast by TXA2 analog
U46619.
TXA2 is an inflammatory mediator that can modulate
a variety of important biologic functions, including coagula-
tion and vasomotor and bronchomotor reactivity.31 Several
report shows that adequate physiologic concentration of
U46619 (TXA2 analog) is 10
8e106 M.32,33 Our previous
study showed that 2 107 nM of U46619 showed highest
activity of fibroblast migration,34 then we chose this
concentration for stimulator of migration.
Clarithromycin had no effect on fibroblast contraction
which is another function and final process of wound
healing. Not like other drugs which effect on fibroblast
migration,35,36 CAM effect might be limited in early part of
wound healing process.
The mechanism of CAM effect on the fibroblast migration
is not clear. Previous studies demonstrate that several
mediators that inhibit the lung fibroblast migration are
related to the protein kinase A (PKA).17,37 The current study
indicated that CAM effect but PGD2 on HFL-1 migration was
related to protein kinase A (Fig. 9). We had also tried but
fail to show the effect of CAM on the p38 activity that is
related to cell migration38 (data not shown). Continuous
study of CAM mechanism would be required.
There are no clinical trials with CAM for treatment of
fibroblast related to wound healing such as IPF. However,
there are in vivo experiment reports which show macrolide
effects on mouse models of idiopathic pulmonary fibrosis.
Fourteen-membered ring macrolides inhibit bleomycin-
induced acute lung injury.39,40 Recent studies have shown
that both COPD and asthma are also associated with fibrosis
of small airways.41,42 We might be able to expand the treat-
ment territory with CAM even to COPD and asthma, and to
use CAM. There is a possibility of using CAM for treatment of
these diseases.
In summary, the current study demonstrated that clar-
ithromycin could inhibit fibroblast migration. This effect of
CAM could potentially reduce the tissue remodeling and
relieve the diseases of fibrotic.
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